In order to be eligible to supply ACTs under the AMFm, a manufacturer must meet the criteria set out in the Global Fund’s Quality Assurance Policy. In keeping with the AMFm objective of countering resistance to artemisinin, manufacturers must also commit to not market oral artemisinin monotherapies for the treatment of the patients. Participating manufacturers will sign a contract with the Global Fund which sets out the conditions of supplying ACTs under the AMFm.
Contact | Report Fraud and Abuse | Legal | RSS | Sitemap
© 2013 The Global Fund to Fight AIDS, Tuberculosis and Malaria